Evidence map›Paper›PMID 42461348›Full record

ArticleJournal of cancer survivorship : research and practice2026

The Survivorship Passport for childhood cancer survivors: improvements and experience within several European PanCare projects.

Monica Muraca, Davide Saraceno, Giulia Stabile, Alessandra Berti, Thokozani Reuben Ngidi, Catherine Chronaki, Giorgio Cangioli, Roberta Gazzarata, Brigitte Nicolas, Andrea Beccaria and 29 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Monica MuracaDOPO Clinic, Division of Pediatric Hematology and Oncology, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147, Genoa, Italy. monicamuraca@gaslini.org.
Davide SaracenoCineca Interuniversity Consortium, Bologna, Italy.
Giulia StabileCineca Interuniversity Consortium, Bologna, Italy.
Alessandra BertiCineca Interuniversity Consortium, Bologna, Italy.
Thokozani Reuben NgidiCineca Interuniversity Consortium, Bologna, Italy.
Catherine ChronakiHL7 Europe, Brussels, Belgium.
Giorgio CangioliHL7 Europe, Brussels, Belgium.
Roberta GazzarataHL7 Europe, Brussels, Belgium.
Brigitte NicolasDOPO Clinic, Division of Pediatric Hematology and Oncology, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147, Genoa, Italy.
Andrea BeccariaDOPO Clinic, Division of Pediatric Hematology and Oncology, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147, Genoa, Italy.
Ramona TalloneDOPO Clinic, Division of Pediatric Hematology and Oncology, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147, Genoa, Italy.
Sara ObertiDOPO Clinic, Division of Pediatric Hematology and Oncology, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147, Genoa, Italy.
Lisa PelanconiDOPO Clinic, Division of Pediatric Hematology and Oncology, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147, Genoa, Italy.
Francesca BagnascoEpidemiology and Biostatistics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Giacomo CavalcaUniversity of Bologna, Bologna, Italy.
Julia Balaguer GullInstituto de, Investigación Sanitaria La Fe - Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Maria Teresa Tormo AlcañizInstituto de, Investigación Sanitaria La Fe - Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Antonio Orduña GalanInstituto de, Investigación Sanitaria La Fe - Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Anne UyttebroeckDepartment of Oncology, Paediatric Oncology, KU Leuven; Department of Paediatric Haematology and Oncology, University Hospitals Leuven, Leuven, Belgium.
Tom BriéIT Department, University Hospitals Leuven, Leuven, Belgium.
Erik Vanden MeerschNexuzhealth, University Hospitals Leuven, Leuven, Belgium.
Jelena RasconCenter for Pediatric Oncology and Hematology, Information and Technology Development Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Monika KapitančukėCenter for Pediatric Oncology and Hematology, Information and Technology Development Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Justas TrinkūnasVilnius Gediminas Technical University, Vilnius, Lithuania.
Thorsten LangerPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Anke NeumannInstitute of Medical Biometry and Statistics, Section for Clinical Research-IT, University of Luebeck and University Hospital Schleswig-Holstein, Lübeck, Germany.
Ruth LadensteinAnna Children's Cancer Research Institute, Vienna, Austria.
Edit BardiAnna Children's Cancer Research Institute, Vienna, Austria.
Stefan BeyerCenter for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Vienna, Austria.
Günter SchreierCenter for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Vienna, Austria.
Gerald GredingerGesundheit Österreich GmbH, Vienna, Austria.
Kylie O'BrianPintail, Limited, Dublin, Ireland.
Anna-Liesa FilibertDivision of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics, German Childhood Cancer Registry University Medical Centerof the Johannes Gutenberg University Mainz, Mainz, Germany.
Rebecca van KalsbeekPrincess Máxima Centre for Paediatric Oncology, Utrecht, Netherlands.
Helena van der PalPrincess Máxima Centre for Paediatric Oncology, Utrecht, Netherlands.
Leontien KremerPrincess Máxima Centre for Paediatric Oncology, Utrecht, Netherlands.
Desiree GrabowDivision of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics, German Childhood Cancer Registry University Medical Centerof the Johannes Gutenberg University Mainz, Mainz, Germany.
Riccardo HauptDOPO Clinic, Division of Pediatric Hematology and Oncology, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147, Genoa, Italy.
with the contribution of PanCareFollowUp and PanCareSurPass consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background/purposeAs the population of childhood cancer survivors (CCS) continues to grow, personalized long-term follow-up (LTFU) care has become essential for ensuring optimal quality of life. The Survivorship Passport (SurPass) was developed to support efficient delivery of high-quality LTFU care, with the provision of treatment summaries and personalized follow-up recommendations. Updates to SurPass, from version v1.1 to v2.0, were made possible through two complementary European-funded projects: PanCareFollowUp and PanCareSurPass.

methodsWithin PanCareFollowUp, SurPass was updated with new variables and algorithms based on International Guideline Harmonization Group/PanCare guidelines (v1.2) and tested in one clinic. During PanCareSurPass, the platform was updated to v2.0, featuring certification as Medical Device (MD) and interoperability with Electronic Health Information Systems, and deployed across clinical sites in six European countries.

resultsThe current SurPass v2.0 includes 242 variables and 47 algorithms for generation of the Standardized Care Plan. It is certified as MD and supports both manual and semi-automatic data entry through the adoption of Health Level Seven International Fast Healthcare Interoperability Resources (HL7-FHIR). The preliminary experience with SurPass delivered to 207 CCS in Italy within the PanCareFollowUp is reported.

conclusionInteroperability via HL7-FHIR and the MD certification of the SurPass allow its use in clinical practice, and a reduction in time needed to generate the document providing homogeneous and personalized LTFU care for European CCS. Cost of interoperability through HL7-FHIR is offset by savings due to time reduction for TS generation. Experience in one clinic document the satisfaction of survivors who shared the document with their family doctors. IMPLICATIONS FOR CANCER SURVIVORS: The Survivorship Passport (SurPass) provides childhood cancer survivors with a standardized, personalized summary of their cancer treatment and individualized follow-up recommendations based on international guidelines. Its implementation across multiple European countries demonstrates the feasibility of delivering consistent survivorship information that can support long-term follow-up, facilitate communication between survivors and healthcare providers, and promote informed engagement in survivorship care.

Indexed as

Cancer treatment summaryCare planChildhood cancer survivorsData standardizationEuropean Health Data SpaceHL7 Europe Cancer Common Data ModelHL7-FHIRInteroperabilityLate effectsLong-term follow-upPanCareFollowUpPanCareSurPassPersonalized survivorship careSurvivorship

Identifiers

PMID42461348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.